Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa:
7 days ago
- #immunogenicity
- #COVID-19 vaccines
- #HIV
- Study evaluates safety and immunogenicity of single-dose COVID-19 vaccines (Ad26.COV2.S, BNT162b2, SARS-CoV-2-rS-protein-nanoparticle) in vaccinated/unvaccinated adults with and without HIV in South Africa.
- Phase 2a randomized, observer-blind trial included 694 participants (599 with HIV, 95 without), assessing humoral immune responses (binding/neutralizing antibodies) and safety up to 12 months post-vaccination.
- BNT162b2 induced the highest peak humoral response, but all vaccines were safe and effective, regardless of CD4 count or viral suppression in people with HIV.
- Findings support the use of these vaccine strategies in low- and middle-income countries, aligning with WHO recommendations for immunosuppressed individuals.